- Home
- CAN vs PROK Comparison
CAN vs PROK Comparison
Compare CAN & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CAN
- PROK
- Stock Information
- Founded
- CAN 2013
- PROK 2015
- Country
- CAN Singapore
- PROK United States
- Employees
- CAN N/A
- PROK N/A
- Industry
- CAN Semiconductors
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CAN Technology
- PROK Health Care
- Exchange
- CAN Nasdaq
- PROK Nasdaq
- Market Cap
- CAN 330.5M
- PROK 384.2M
- IPO Year
- CAN 2019
- PROK N/A
- Fundamental
- Price
- CAN $0.78
- PROK $2.52
- Analyst Decision
- CAN Strong Buy
- PROK Buy
- Analyst Count
- CAN 6
- PROK 5
- Target Price
- CAN $2.50
- PROK $6.25
- AVG Volume (30 Days)
- CAN 34.8M
- PROK 2.4M
- Earning Date
- CAN 08-14-2025
- PROK 08-12-2025
- Dividend Yield
- CAN N/A
- PROK N/A
- EPS Growth
- CAN N/A
- PROK N/A
- EPS
- CAN N/A
- PROK N/A
- Revenue
- CAN $345,360,000.00
- PROK $527,000.00
- Revenue This Year
- CAN $115.67
- PROK $265.05
- Revenue Next Year
- CAN $63.75
- PROK N/A
- P/E Ratio
- CAN N/A
- PROK N/A
- Revenue Growth
- CAN 82.40
- PROK N/A
- 52 Week Low
- CAN $0.53
- PROK $0.46
- 52 Week High
- CAN $3.27
- PROK $7.13
- Technical
- Relative Strength Index (RSI)
- CAN 55.55
- PROK 49.64
- Support Level
- CAN $0.64
- PROK $2.30
- Resistance Level
- CAN $0.77
- PROK $2.53
- Average True Range (ATR)
- CAN 0.05
- PROK 0.19
- MACD
- CAN 0.01
- PROK -0.02
- Stochastic Oscillator
- CAN 78.14
- PROK 74.44
About CAN Canaan Inc.
Canaan Inc is a developer of supercomputing chips and the manufacturer of digital blockchain computing equipment and the supplier of the overall scheme for computer software and hardware of digital blockchain. The revenues of the company are derived from the sales of Bitcoin mining machines and related parts and accessories. Geographically, the company derives its maximum revenue from United States.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.